Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $142.89 | 12 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $142.89 | 12 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2018 | $24.38 | 2 | Astellas Pharma US Inc ($24.38) |
| 2017 | $118.51 | 10 | Astellas Pharma US Inc ($118.51) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/01/2018 | Astellas Pharma US Inc | VESICARE (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $10.71 | General |
| Category: UROLOGY | ||||||
| 01/11/2018 | Astellas Pharma US Inc | VESICARE (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $13.67 | General |
| Category: UROLOGY | ||||||
| 12/07/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Vesicare | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: Urology | ||||||
| 09/21/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Vesicare | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: Urology | ||||||
| 08/17/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Vesicare | Food and Beverage | In-kind items and services | $8.25 | General |
| Category: Urology | ||||||
| 07/20/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Vesicare | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: Urology | ||||||
| 06/08/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Vesicare | Food and Beverage | In-kind items and services | $11.69 | General |
| Category: Urology | ||||||
| 05/18/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Vesicare | Food and Beverage | In-kind items and services | $9.81 | General |
| Category: Urology | ||||||
| 04/13/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Vesicare | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: Urology | ||||||
| 03/23/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Vesicare | Food and Beverage | In-kind items and services | $8.88 | General |
| Category: Urology | ||||||
| 02/16/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Vesicare | Food and Beverage | In-kind items and services | $8.25 | General |
| Category: Urology | ||||||
| 01/26/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Xtandi | Food and Beverage | In-kind items and services | $8.81 | General |
| Category: Urology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 79 | 84 | $15,042 | $4,382 |
| 2022 | 3 | 53 | 61 | $10,980 | $3,269 |
| 2021 | 2 | 38 | 43 | $7,590 | $2,326 |
| 2020 | 1 | 18 | 18 | $2,340 | $799.61 |
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 27 | $6,885 | $1,866 | 27.1% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2023 | 39 | 39 | $5,655 | $1,663 | 29.4% |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | Office | 2023 | 18 | 18 | $2,502 | $852.84 | 34.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 21 | $5,355 | $1,491 | 27.8% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2022 | 26 | 26 | $3,665 | $1,113 | 30.4% |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | Office | 2022 | 14 | 14 | $1,960 | $664.80 | 33.9% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2021 | 27 | 27 | $3,510 | $1,166 | 33.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 11 | 16 | $4,080 | $1,160 | 28.4% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2020 | 18 | 18 | $2,340 | $799.61 | 34.2% |
About Dr. Ernest Topran, MD
Dr. Ernest Topran, MD is a Gynecology healthcare provider based in Cheshire, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1710911722.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ernest Topran, MD has received a total of $142.89 in payments from pharmaceutical and medical device companies, with $24.38 received in 2018. These payments were reported across 12 transactions from 1 company. The most common payment nature is "Food and Beverage" ($142.89).
As a Medicare-enrolled provider, Topran has provided services to 188 Medicare beneficiaries, totaling 206 services with total Medicare billing of $10,776. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Practice Information
- Specialty Gynecology
- Other Specialties Obstetrics
- Location Cheshire, CT
- Active Since 07/10/2006
- Last Updated 09/09/2008
- Taxonomy Code 207VG0400X
- Entity Type Individual
- NPI Number 1710911722
Products in Payments
- Myrbetriq (Drug) $118.51
- VESICARE (Drug) $24.38
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.